[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345852-105":59,"doc-detail-345852-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","intraprostatic-steroid-hormones-and-endocrine-disruptors-in-prostate-cancer-research","Intraprostatic steroid hormones and endocrine disruptors in prostate cancer - Research","","Prostate cancer is a hormone-dependent malignancy shaped by steroid signaling, yet the intraprostatic steroid landscape and the contribution of endocrine-disrupting chemicals (EDCs) remain insufficiently mapped. This study comprehensively profiles intraprostatic steroids and EDCs across cancerous tissue, non-cancerous prostate zones, and plasma from 173 localized prostate cancer patients undergoing robot-assisted prostatectomy. Liquid chromatography–tandem mass spectrometry quantified 30 steroids and 16 EDCs, linking steroid and EDC patterns to tumor aggressiveness, prognosis, and risk stratification, with machine learning improving risk classification beyond clinical variables.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/intraprostatic-steroid-hormones-and-endocrine-disruptors-in-prostate-cancer-research/345852/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/intraprostatic-steroid-hormones-and-endocrine-disruptors-in-prostate-cancer-research/345852.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of this study on prostate cancer?","Question",{"text":112,"@type":113},"To comprehensively profile intraprostatic steroid hormones and endocrine-disrupting chemicals (EDCs) and evaluate their associations with tumor aggressiveness, prognosis, and risk categories.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were steroids and EDCs measured in patients?",{"text":117,"@type":113},"Steroids and EDCs were quantified using liquid chromatography–tandem mass spectrometry (LC-MS/MS) in cancerous tissue, non-cancerous tissues (peripheral and transition zones), and plasma from 173 patients.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about EDCs compared with plasma levels?",{"text":121,"@type":113},"EDCs accumulated in the prostate tissue and were generally not associated with plasma concentrations, suggesting tissue-specific retention rather than faithful reflection by serum.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345852,1790221955,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Endocrine-Related Cancer (2026) 33 e260153  \n[https://doi.org/10.1530/ERC-26-0153](https://doi.org/10.1530/ERC-26-0153)  \nRESEARCH  \nReceived 22 March 2026 Accepted 9 June 2026 Available online 11 June 2026  \nVersion of Record published 15 July 2026  \n\n| Intraprostatic steroid hormones and endocrine disruptors in prostate cancer\u003Cbr>Jana Vitku􀀁1, Tereza Skodova1, Anezka Varausova1, Lukas Gadus2,3, Michal Horenitzky2,3, Marie Novakova4, Martin Hill1, Michaela Svojtkova1, Lucie Kolatorova1, Adela Lukaskova1 and Jiri Heracek2,3\u003Cbr>1Department of Steroids and Proteofactors, Institute of Endocrinology, Prague, Czech Republic\u003Cbr>2Department of Urology, First Faculty of Medicine, Charles University, Prague, Czech Republic\u003Cbr>3Department of Urology, Military University Hospital, Prague, Czech Republic\u003Cbr>4Department of Pathology, Military University Hospital, Prague, Czech Republic\u003Cbr>Correspondence should be addressed to J Vitku: [jvitku@endo.cz](jvitku@endo.cz) |\n| --- |\n| Abstract\u003Cbr>Prostate cancer (PCa) is a hormone-dependent malignancy governed by steroid signaling. Despite characterization of androgen pathways, the broader intraprostatic steroid environment remains underexplored. Endocrine-disrupting chemicals (EDCs) may modulate these processes, yet their tissue distribution is largely unknown. We aimed to comprehensively proﬁle intraprostatic steroids and EDCs and assess their associations with tumor aggressiveness, prognosis, and risk stratiﬁcation. Thirty steroids and 16 EDCs were quantiﬁed using liquid chromatography–tandem mass spectrometry in cancerous tissue, non-cancerous tissues (from peripheral and transition zones), and plasma from 173 patients with localized PCa undergoing robot-assisted radical prostatectomy. Analysis of variance was used to compare analyte levels across biological matrices and according to disease aggressiveness, multivariate statistical models evaluated associations with patient prognosis and risk categories, and machine learning (ML) models were applied for risk stratiﬁcation. Steroid proﬁles differed markedly between plasma and prostate tissue, whereas EDCs accumulated in the prostate and were generally not associated with plasma concentrations. Cancerous tissue showed lower conjugated dehydroepiandrosterone (DHEA) and higher pregnenolone, corticoids, and testosterone compared to non-cancerous tissue. Elevated intratumoral cortisol, cortisone, androstenedione, conjugated testosterone,7-ketoDHEA, and estrone were associated with greater tumor aggressiveness. Higher intratumoral parabens correlated with increased postoperative PSA, while conjugated dihydrotestosterone (DHT) and phytoestrogen daidzein were inversely associated with PSA levels. Higher EDC burden and intratumoral steroid levels were associated with higher risk categories. In contrast, DHT showed a consistent protective proﬁle, being negatively associated with both prognosis and risk classiﬁcation. Integrating steroids and EDCs improved ML-based risk classiﬁcation beyond preoperative clinical variables.\u003Cbr>Keywords: prostate cancer; endocrine disruptor; endocrine-disrupting chemical; steroid hormone; LC-MS/MS |\n\nIntroduction  \nSteroid hormones play a central role in the development of the prostate gland and in maintaining physiological homeostasis in the adult prostate, primarily through androgen- and estrogen-mediated regulation (1, 2) .  \nAndrogens have also long been recognized as key drivers of prostate cancer (PCa); however, growing evidence suggests that additional steroid hormones, including estrogens and progesterone, can contribute  \nPublished by Bioscientiﬁca Ltd.  \n[https://erc.bioscienti](https://erc.bioscienti)ﬁ[ca.com](ca.com)  \n© 2026 the author(s)  \nThis work is licensed under a Creative Commons Attribution 4 .0 International License.  \nJ Vitku et al. Endocrine-Related Cancer (2026) 33 e260153  \n[https://doi.org/10.1530/ERC-26-0153](https://doi.org/10.1530/ERC-26-0153)  \nnot only to tumor initiation but also to diseas","cbCaitqdp6ZJuzB9","https://ap.wps.com/l/cbCaitqdp6ZJuzB9","pdf",2314489,15,"English","# Abstract\n# Introduction","[{\"question\":\"What was the main goal of this study on prostate cancer?\",\"answer\":\"To comprehensively profile intraprostatic steroid hormones and endocrine-disrupting chemicals (EDCs) and evaluate their associations with tumor aggressiveness, prognosis, and risk categories.\"},{\"question\":\"How were steroids and EDCs measured in patients?\",\"answer\":\"Steroids and EDCs were quantified using liquid chromatography–tandem mass spectrometry (LC-MS/MS) in cancerous tissue, non-cancerous tissues (peripheral and transition zones), and plasma from 173 patients.\"},{\"question\":\"What did the results show about EDCs compared with plasma levels?\",\"answer\":\"EDCs accumulated in the prostate tissue and were generally not associated with plasma concentrations, suggesting tissue-specific retention rather than faithful reflection by serum.\"}]","Intraprostatic steroid hormones and endocrine disruptors in prostate cancer - Research | PDF",1790059122,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66a7d9aa5331fb16f41545b80251ba52.webp",983,1269,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9c9b6d9115b72318331eb4ead6604d8.webp",982,1268,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14a093dbbeee53e60ad9db10176de3f6.webp",981,1266,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65d3f719242f7322ad25a4fa4206da9c.webp",980,1265]